The efficacy of generic imatinib as first- and second-line therapy: three year follow-up of chronic myeloid leukemia patients

We examined the long-term clinical outcomes of CML patients (n=41) receiving generic imatinib as first-line (n=27) and second-line therapy (n=14) in Bosnia and Herzegovina. OS rates for first-line and second-line generic imatinib were 85% vs. 100%, respectively. For first-line generic imatinib, CCyR was 81%. Generic imatinib as second-line therapy does not have deleterious effects on patient outcomes.

Source: Clinical Lymphoma, Myeloma and Leukemia - February 15, 2017 Category: Hematology Authors: Erna Islamagic, Azra Hasic, Sabira Kurtovic, Emina Suljovic Hadzimesic, Lejla Mehinovic, Mirza Kozaric, Amina Kurtovic-Kozaric Tags: Original Study Source Type: research